Zola Predosa (BO), December 3rd, 2024
GVS S.p.A., a global leader in advanced filtration solutions, has announced a binding agreement to acquire Haemonetics Corporation’s Transfusion Medicine business. This acquisition marks a significant milestone for GVS as it strengthens its position in the healthcare filtration sector and expands its global reach.
Massimo Scagliarini, CEO of GVS, expressed the company’s enthusiasm about the acquisition, stating:
“Following the acquisition of STT and Haemotronic, this transaction marks another step in our expansion strategy in the transfusion medicine market, that sees today only one player with a fully vertical business model. With Haemonetics’ business, GVS becomes a global and fully vertically integrated actor, adding complementary and highly synergic assets to its existing product offering and further reinforcing its leadership in the Healthcare filtration sector”.
The acquisition adds Haemonetics’ proprietary solutions for blood collection, processing, filtration, and transfusion to GVS’ portfolio. It also includes manufacturing assets in Covina, California, and part of the Haemonetics’ operations in Tijuana, Mexico, where these products are currently produced.
Strategic Highlights:
- Vertically integrated offerings, from membrane production to medical devices.
- Expanded geographical reach, targeting markets in the US, EMEA, APAC, and LATAM.
- Strengthened position in the $1 billion global whole blood market.
- Synergies through production optimization, cost efficiency, and advanced product development.
Financial
Overview:
The transaction involves an initial purchase price of $44.6 million, with
performance-based payments potentially raising the total to $67.1 million. The
deal is expected to generate over 50 million in revenue for GVS in FY 2025,
with an EV/EBITDA multiple of approximately 6x based on the acquired business's
financials.
The acquisition, set to close in Q1 2025, underscores GVS’ commitment to innovation and long-term growth in the healthcare filtration sector.
Read the full press release here
